SCHEMBL26613508

SCHEMBL26613508

Cc1ccc2c(c1)CCC(c1ccc(C(N)=O)cc1)N2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 1/20 0.53
▸ ESR2 Q92731 1/20 0.53
▸ MAP2K4 P45985 2/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ MAPKAPK2 P49137 1/20 0.40
▸ MAPKAPK3 Q16644 1/20 0.40
▸ MAPK6 Q16659 1/20 0.40
▸ MAPKAPK5 Q8IW41 1/20 0.40
▸ SIRT2 Q8IXJ6 1/20 0.39
▸ PARP1 P09874 1/20 0.39
▸ AR P10275 1/20 0.38
▸ CYP2C9 P11712 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.34
▸ DRD3 P35462 3/20 0.34
▸ DRD2 P14416 2/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26613374 0.91 ESR1 (0.45) ESR1ESR2MAP2K4MAPK1MAPKAPK2
SCHEMBL29746031 0.91 ESR1 (0.45) ESR1ESR2MAP2K4MAPK1MAPKAPK2
SCHEMBL26613419 0.85 ESR1 (0.57) ESR1ESR2SIRT2PARP1
SCHEMBL26613369 0.85 ESR1 (0.53) ESR1ESR2SIRT2PARP1CYP2C9
SCHEMBL29746053 0.81 ESR1 (0.48) ESR1ESR2PARP1CYP2C9CYP3A4
SCHEMBL26613383 0.81 ESR1 (0.48) ESR1ESR2PARP1CYP2C9CYP3A4
SCHEMBL26613392 0.80 ESR1 (0.50) ESR1ESR2
SCHEMBL26613378 0.78 ESR1 (0.44) ESR1ESR2SIRT2ALDH1A1HPGD
SCHEMBL26613564 0.77 ESR1 (0.47) ESR1ESR2ALDH1A1SMN1; SMN2
SCHEMBL26613470 0.74 ESR1 (0.47) ESR1ESR2ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260083723-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS TORAY INDUSTRIES, INC. (JP) 2026-03-26 — — US claimed
US-12570639-B2 Tetrahydroquinoline derivative and medicinal use thereof TORAY INDUSTRIES, INC. (JP) 2026-03-10 — — US claimed
EP-4545079-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS Toray Industries, Inc. (JP) 2025-04-30 — — EP claimed
CN-119403554-A Therapeutic or prophylactic agent for amyotrophic lateral sclerosis 东丽株式会社 2025-02-07 — — CN claimed
US-20240116903-A1 TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF TORAY INDUSTRIES, INC. (JP) 2024-04-11 — — US claimed
WO-2023249107-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR PERIPHERAL NERVE DISORDER 東レ株式会社 2023-12-28 — — WO claimed
WO-2023249106-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS 東レ株式会社 2023-12-28 — — WO claimed
WO-2023249105-A1 THERAPEUTIC AGENT OR PREVENTIVE AGENT FOR DRUG-INDUCED MYOCARDIAL DISORDERS 東レ株式会社 2023-12-28 — — WO claimed
EP-4269392-A1 TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF Toray Industries, Inc. (JP) 2023-11-01 — — EP claimed
CN-116648245-A Tetrahydroquinoline derivative and medical application thereof 东丽株式会社 2023-08-25 — — CN claimed
WO-2022138888-A1 TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF 東レ株式会社 2022-06-30 — — WO claimed
US-20260083723-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS TORAY INDUSTRIES, INC. (JP) 2026-03-26 — — US disclosed
US-12570639-B2 Tetrahydroquinoline derivative and medicinal use thereof TORAY INDUSTRIES, INC. (JP) 2026-03-10 — — US disclosed
EP-4545079-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS Toray Industries, Inc. (JP) 2025-04-30 — — EP disclosed
CN-119403554-A Therapeutic or prophylactic agent for amyotrophic lateral sclerosis 东丽株式会社 2025-02-07 — — CN disclosed
WO-2023249106-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS 東レ株式会社 2023-12-28 — — WO disclosed
EP-4269392-A1 TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF Toray Industries, Inc. (JP) 2023-11-01 — — EP disclosed
EP-4269392-A1 TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF Toray Industries, Inc. (JP) 2023-11-01 — — EP disclosed
CN-116648245-A Tetrahydroquinoline derivative and medical application thereof 东丽株式会社 2023-08-25 — — CN disclosed
WO-2022138888-A1 TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF 東レ株式会社 2022-06-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240116903-A1 TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF AIFM2, TXNRD2, NFE2L2 ESR1 3731/4885ESR2 1215/4885MAP2K4 3442/4885
US-20260083723-A1 THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS AIFM2, GPX1, SOD1 ESR1 3396/4885ESR2 860/4885MAP2K4 4708/4885
US-12570639-B2 Tetrahydroquinoline derivative and medicinal use thereof AIFM2, GPX1, GPX4 ESR1 3178/4885ESR2 411/4885MAP2K4 3913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback